Management of Infantile Hemangioma
|
||||||||||||
CME Information
Course Overview |
Infantile hemangioma (IH) is the most common tumor of childhood and is estimated to affect about 4 to 5 percent of children. With a course of expectant observation, many patients experience a complete involution without significant sequelae. However, in a fraction of patients, early referral for treatment is important.
Currently available treatments include pharmacological interventions (such as beta-blockers and steroids) and surgical interventions (such as laser therapy or excision in appropriate cases). The beta-blocker propranolol was approved by the U.S. Food and Drug Administration (FDA) in March 2014 as a treatment for IH and is typically the first-line treatment choice in children without contraindications.
Uncertainty remains around which interventions might be most beneficial as first-line therapies, when alternative or adjunctive therapies are appropriate after first-line treatment is unsuccessful, and how the disease site informs treatment decisions. This review aims to address some of these issues.
Educational Objectives |
At the conclusion of this activity, the participant should be able to:
Describe the evidence regarding the efficacy, comparative effectiveness, and harms of therapies for infantile hemangioma.
Describe the gaps in the current evidence base and areas needing additional research regarding the comparative effectiveness of treatments for infantile hemangioma.
Target Audience |
back to top |
This CME activity is designed to meet the educational needs of primary care physicians, pediatricians, pediatric dermatologists, pediatric otolaryngologists, surgeons, physician assistants, nurse practitioners, and other health care professionals who treat children with infantile hemangioma.
Method of Participation |
This activity is in PDF and HTML formats and is accompanied by references linked to PubMed abstracts.
To receive a maximum of 0.50 AMA PRA Category 1 Credit(s)™ you should:
- View the materials in this enduring material.
- Complete the posttest (you must answer 4 out of 5 questions correctly).
- Complete and submit the CME registration and evaluation forms.
The estimated time to complete this activity, including review of the materials, is 0.50 hour(s).
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.
If you have questions about the participation process, please e-mail the Office of Continuing Medical Education, cme@bcm.edu or phone 713.798.8237.
Accreditation/Credit Designation |
back to top |
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Term of Approval |
June 2016 through June 2018. Original release date: June 2016
Peer Review |
back to top |
In June 2016, this continuing medical education online enduring material was reviewed by Mary E. Lindholm, M.D., Clinical Associate Professor of Family Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again in June 2018.
Disclosure: Nothing to disclose.
Program Director |
back to top |
Michael Fordis, M.D.
Sr. Associate Dean and Director, Center for Collaborative and Interactive Technologies
Director, The John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.
Disclaimer |
This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.
Baylor College of Medicine makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site's terms and conditions of use including copyright and licensing restrictions.
Disclosure |
back to top |
The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support SM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.
Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.
If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.
The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:
Geetha Achanta, M.Sc., Ph.D., Medical Writer
Managing Editor
Center for Collaborative and Interactive Technologies
Baylor College of Medicine
Houston, TexasDisclosure: Nothing to disclose.
Raegan Hunt, M.D., Ph.D., Contributor
Assistant Professor of Dermatology and Pediatrics
Texas Children's Hospital
Houston, TexasDisclosure: Nothing to disclose.
Mary E. Lindholm, M.D., Peer Reviewer
Clinical Associate Professor of Family Medicine
University of Massachusetts Medical School
Worcester, MassachusettsDisclosure: Nothing to disclose.
Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.
Baylor College of Medicine requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
Acknowledgement of Support |
This CME activity is supported by a contract, HHSA290201410015C, from the Agency for Healthcare Research and Quality.
| back to top |